Literature DB >> 2477997

Effects of prostaglandins and cAMP levels on monocyte IL-1 production.

S Kassis1, J C Lee, N Hanna.   

Abstract

The effects of prostaglandin E2 (PGE2), as well as other cAMP-elevating agents, on the in vitro production of interleukin-1 (IL-1) by human monocytes (HM) were examined. Exposure to E. coli lipopolysacharide (LPS) resulted in a dose- and time-dependent increase of IL-1 activity in monocytes culture supernatants. Maximal levels of secreted IL-1 in response to 10 ng LPS/ml were obtained at 18 h. PGE1, PGE2, cholera toxin (CT) and the phosphodiesterase inhibitor, isobutylmethylxanthin (IBMX), when added with LPS, resulted in a dose-dependent increase in cellular cAMP and in secreted IL-1. Maximal levels of secreted IL-1 were 2.5-5.0-fold over LPS alone. When CT or PGE2 was added with IBMX a further increase was observed. These agents exhibited marginal effect on cell-associated IL-1. Maximum cAMP levels was achieved at 10 min in response to either PGE1 or PGE2 and returned to near basal levels after 18 h. While PGE1 elevated cAMP to a larger extent than PGE2 (58- vs. 30-fold) the latter resulted in a higher levels of secreted IL-1. Elevated cAMP persisted throughout the entire culture period in response to CT (4-6-fold) or IBMX (7-fold). Thus, we conclude that in adherent HM, IL-1 production is potentiated and not inhibited by prostaglandins or agents that elevate cellular cAMP.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2477997     DOI: 10.1007/bf01972795

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  8 in total

1.  Regulation of interleukin 1 production by mouse peritoneal macrophages. Effects of arachidonic acid metabolites, cyclic nucleotides, and interferons.

Authors:  S R Brandwein
Journal:  J Biol Chem       Date:  1986-07-05       Impact factor: 5.157

2.  Mechanism of action of cholera toxin on intact cells. Generation of A1 peptide and activation of adenylate cyclase.

Authors:  S Kassis; J Hagmann; P H Fishman; P P Chang; J Moss
Journal:  J Biol Chem       Date:  1982-10-25       Impact factor: 5.157

3.  Different mechanisms of desensitization of adenylate cyclase by isoproterenol and prostaglandin E1 in human fibroblasts. Role of regulatory components in desensitization.

Authors:  S Kassis; P H Fishman
Journal:  J Biol Chem       Date:  1982-05-10       Impact factor: 5.157

4.  Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate.

Authors:  P J Knudsen; C A Dinarello; T B Strom
Journal:  J Immunol       Date:  1986-11-15       Impact factor: 5.422

5.  Participation of monocyte-macrophages and lymphocytes in the production of a factor that stimulates collagenase and prostaglandin release by rheumatoid synovial cells.

Authors:  J M Dayer; J Bréard; L Chess; S M Krane
Journal:  J Clin Invest       Date:  1979-11       Impact factor: 14.808

6.  Arachidonic acid metabolites regulate interleukin-1 production.

Authors:  S L Kunkel; S W Chensue
Journal:  Biochem Biophys Res Commun       Date:  1985-04-30       Impact factor: 3.575

7.  A modified assay for interleukin-1 (IL-1).

Authors:  P L Simon; J T Laydon; J C Lee
Journal:  J Immunol Methods       Date:  1985-11-28       Impact factor: 2.303

8.  Potentiation of the T-lymphocyte response to mitogens. I. The responding cell.

Authors:  I Gery; R K Gershon; B H Waksman
Journal:  J Exp Med       Date:  1972-07-01       Impact factor: 14.307

  8 in total
  10 in total

1.  Increased cyclic AMP levels enhance IL-1 alpha and IL-1 beta mRNA expression and protein production in human myelomonocytic cell lines and monocytes.

Authors:  S S Sung; J A Walters
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

2.  Tumor necrosis factor alpha, interleukin-1 alpha, interleukin-6, and prostaglandin E2 production in murine peritoneal macrophages infected with Ehrlichia risticii.

Authors:  A M van Heeckeren; Y Rikihisa; J Park; R Fertel
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

3.  Inhibition of interleukin-1 (IL-1) and tumor necrosis factor (TNF) production by pyridinyl imidazole compounds is independent of cAMP elevating mechanisms.

Authors:  S Kassis; U Prabhakar; J C Lee
Journal:  Agents Actions       Date:  1993

4.  Effects of the prostaglandin analogue misoprostol on inflammatory mediator release by human monocytes.

Authors:  D L Widomski; R E Walsh; D A Baron; M I Hidvegi; D J Fretland; P W Collins; T S Gaginella
Journal:  Agents Actions       Date:  1991-09

5.  The prostaglandin E1 analogue, misoprostol, regulates inflammatory cytokines and immune functions in vitro like the natural prostaglandins E1, E2 and E3.

Authors:  D R Haynes; M W Whitehouse; B Vernon-Roberts
Journal:  Immunology       Date:  1992-06       Impact factor: 7.397

6.  Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells.

Authors:  J D Cleary; S W Chapman; R L Nolan
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

Review 7.  Toxins-useful biochemical tools for leukocyte research.

Authors:  Susana Cubillos; Johannes Norgauer; Katja Lehmann
Journal:  Toxins (Basel)       Date:  2010-03-26       Impact factor: 4.546

8.  Differential regulation of TNF-alpha and IL-1beta production from endotoxin stimulated human monocytes by phosphodiesterase inhibitors.

Authors:  K L Molnar-Kimber; L Yonno; R J Heaslip; B M Weichman
Journal:  Mediators Inflamm       Date:  1992       Impact factor: 4.711

9.  Defective production of interferon-gamma and tumour necrosis factor-alpha by AIDS mononuclear cells after in vitro exposure to Rhodococcus equi.

Authors:  S Delia; C M Mastroianni; M Lichtner; F Mengoni; S Moretti; V Vullo
Journal:  Mediators Inflamm       Date:  1995       Impact factor: 4.711

10.  Cyclic AMP stimulates platelet-derived growth factor B chain mRNA expression in murine macrophage cell lines.

Authors:  E J Kovacs; S Vanstedum
Journal:  Mediators Inflamm       Date:  1995       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.